Camlin Fine Sciences Ltd Q1 FY27 Earnings Analysis

- **Vanillin Business**: Targeting 4,000 tons volume, with FY27 U.S. vanillin sales estimated at 2,200 to 2,400 metric tons (both methyl and ethyl vanillin). Ethyl vanillin campaign planned for 600 tons with 50% order book coverage. Expect volume growth in Europe and U.S. as tariff impact eases. - **Blends Business**: Expected to grow from INR1,050 crores in FY26 to over INR1,400 crores in FY27, supported by global sales force expansion. - **Overall Revenue**: Projected top-line between INR2,200 to INR2,400 crores in FY27, with EBITDA margins of 12-14%. - **Performance Chemicals**: Limited focus and small contribution expected; growth is not a priority. - **Growth Challenges**: Working capital and logistics remain major constraints despite good order books. - **Outlook**: Anticipate stable or improving market conditions with steady growth of 10-15% over next two quarters.

- FY 2027 revenue guidance is maintained at INR 2,200 to 2,400 crores with EBITDA margin between 12%-14%. - Vanillin business expected to deliver INR 200 crores EBITDA at current realizations of $13.5-$14. - Blends business targeted to grow to INR 1,400 crores revenue with EBITDA breakeven for Vinpai and Vitafor at $14-16 million each. - Working capital and logistics remain challenges, potentially impacting cash flow. - EBITDA breakeven anticipated for Vinpai and Vitafor businesses in FY 2027. - Management confident of stable growth (~10%-15%) in the next two quarters despite freight and raw material cost pressures. - No significant increase in employee costs expected beyond current levels. - Capital infusion is a last resort; company pursuing structured debt and bank finance to support growth and liquidity.

- Camlin Fine Sciences is exploring converting an existing plant into a multipurpose facility to reduce raw material costs and improve efficiency. - No specific mention of large-scale new capital expenditure; focus appears on strategic modifications and operational improvements. - Investment in human capital continues, especially for scaling up the Blends business which is expected to grow exponentially. - The company is strengthening its field force globally to support growth in Vinpai and Vitafor operations. - Capital infusion is considered a last resort; current financing plans focus on debt options (structured and bank debt) to support growth and working capital needs. - No explicit announcement of large future capex projects, but ongoing plant modifications and scaling of operations indicate targeted strategic investments.

- Camlin Fine Sciences is currently looking at raising funds through debt, considering both structured debt and bank loans. - Equity infusion is considered a last resort and is not currently on the table, though the authorized capital was increased in March as a contingency. - They are exploring a combination of structured finance and bank debt depending on the location, e.g., structured debt in India and bank debt in Mexico. - The cost of debt is uncertain and depends on market risk assessments, but they aim to keep borrowing costs minimal. - The company is seeking additional liquidity to support growth and manage working capital challenges caused by geopolitical conflicts.

- The ethyl vanillin campaign is planned for 600 tons. - Currently, there is an order book covering 50% of this 600-ton campaign. - Additional stock maintenance is planned since production shift from methyl to ethyl vanillin requires continuous market presence. - Overall vanillin demand is projected around the 4,000-ton mark, considered very doable by management. - The company faces challenges in longer working capital cycles, logistics, and cash flow rather than market demand. - For FY 2027, the company is confident about fulfilling a certain quantum of supply regardless of pricing or cost fluctuations, supported by a healthy order book. - In the Blends business, FY26 revenue was INR1,050 crores, with an expected increase to upwards of INR1,400 crores in FY27, backed by a growing global field force. - U.S. vanillin volume target for FY27 is around 2,200 to 2,400 metric tons, with several contracts already secured.